Pulse Biosciences (PLSE) Cash from Operations (2015 - 2025)

Pulse Biosciences has reported Cash from Operations for 11 years, with the latest figure at -$14.8 million in Q4 2025.

• On a quarterly basis, Cash from Operations fell 61.36% year-over-year to -$14.8 million in Q4 2025; TTM through Dec 2025 was -$54.1 million, a 48.92% decrease from a year earlier, with the FY2025 full-year figure at -$54.1 million, down 48.92% from the prior year.
• Cash from Operations was -$14.8 million for Q4 2025 at Pulse Biosciences, down from -$13.0 million in the prior quarter.
• The five-year high for Cash from Operations was -$6.6 million in Q1 2023, with the low at -$16.4 million in Q2 2021.
• Average Cash from Operations over 5 years is -$11.2 million, with a median of -$11.2 million recorded in 2021.
• The sharpest annual moves came in 2021 and 2023: Cash from Operations tumbled 106.15% in 2021, then soared 57.87% in 2023.
• Over 5 years, Cash from Operations stood at -$12.7 million in 2021, then surged by 37.25% to -$8.0 million in 2022, then rose by 14.85% to -$6.8 million in 2023, then plunged by 34.83% to -$9.1 million in 2024, then sank by 61.36% to -$14.8 million in 2025.
• The last three Cash from Operations figures came in at -$14.8 million (Q4 2025), -$13.0 million (Q3 2025), and -$12.8 million (Q2 2025), per Business Quant data.